• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阳离子脂质组成对 siRNA 脂质纳米粒制剂摄取和细胞内处理的影响。

Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA.

机构信息

Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12.

DOI:10.1016/j.nano.2012.05.019
PMID:22698807
Abstract

UNLABELLED

The in vivo gene silencing potencies of lipid nanoparticle (LNP)-siRNA systems containing the ionizable cationic lipids DLinDAP, DLinDMA, DLinKDMA, or DLinKC2-DMA can differ by three orders of magnitude. In this study, we examine the uptake and intracellular processing of LNP-siRNA systems containing these cationic lipids in a macrophage cell-line in an attempt to understand the reasons for different potencies. Although uptake of LNP is not dramatically influenced by cationic lipid composition, subsequent processing events can be strongly dependent on cationic lipid species. In particular, the low potency of LNP containing DLinDAP can be attributed to hydrolysis by endogenous lipases following uptake. LNP containing DLinKC2-DMA, DLinKDMA, or DLinDMA, which lack ester linkages, are not vulnerable to lipase digestion and facilitate much more potent gene silencing. The superior potency of DLinKC2-DMA compared with DLinKDMA or DLinDMA can be attributed to higher uptake and improved ability to stimulate siRNA release from endosomes subsequent to uptake.

FROM THE CLINICAL EDITOR

This study reports on the in vivo gene silencing potency of lipid nanoparticle-siRNA systems containing ionizable cationic lipids. It is concluded that the superior potency of DLinKC2-DMA compared with DLinKDMA or DLinDMA can be attributed to their higher uptake thus improved ability to stimulate siRNA release from endosome.

摘要

未加标签

含有可离子化阳离子脂质的脂质纳米颗粒(LNP)-siRNA 系统的体内基因沉默效力可能相差三个数量级。在这项研究中,我们试图了解不同效力的原因,研究了含有这些阳离子脂质的 LNP-siRNA 系统在巨噬细胞系中的摄取和细胞内加工。尽管 LNP 的摄取不受阳离子脂质组成的显著影响,但随后的加工事件可能强烈依赖于阳离子脂质种类。特别是,含有 DLinDAP 的 LNP 效力低,可归因于摄取后内源性脂肪酶的水解。不含酯键的含有 DLinKC2-DMA、DLinKDMA 或 DLinDMA 的 LNP 不易受到脂肪酶消化,并促进更有效的基因沉默。与 DLinKDMA 或 DLinDMA 相比,DLinKC2-DMA 的优越效力可归因于更高的摄取和摄取后从内涵体中刺激 siRNA 释放的能力提高。

临床编辑按语

本研究报告了含有可离子化阳离子脂质的脂质纳米颗粒-siRNA 系统的体内基因沉默效力。结论是,与 DLinKDMA 或 DLinDMA 相比,DLinKC2-DMA 的优越效力可归因于其更高的摄取率,从而提高了从内涵体中刺激 siRNA 释放的能力。

相似文献

1
Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA.阳离子脂质组成对 siRNA 脂质纳米粒制剂摄取和细胞内处理的影响。
Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12.
2
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.阳离子脂质组成对抗原呈递细胞中 siRNA 的脂质纳米粒制剂基因沉默特性的影响。
Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4.
3
Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs.深入了解脂质纳米颗粒的细胞摄取机制和小RNA的细胞内释放。
Pharm Res. 2014 Oct;31(10):2685-95. doi: 10.1007/s11095-014-1366-7. Epub 2014 Apr 17.
4
Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.小分子配体增强 siRNA 脂质纳米粒制剂的细胞内递送。
Nanomedicine. 2013 Jul;9(5):665-74. doi: 10.1016/j.nano.2012.11.006. Epub 2012 Dec 6.
5
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.粒径对 siRNA 脂质纳米粒制剂体内效力的影响。
J Control Release. 2016 Aug 10;235:236-244. doi: 10.1016/j.jconrel.2016.05.059. Epub 2016 May 26.
6
On the role of helper lipids in lipid nanoparticle formulations of siRNA.关于辅助脂质在 siRNA 脂质纳米粒制剂中的作用。
Nanoscale. 2019 Nov 21;11(45):21733-21739. doi: 10.1039/c9nr09347h.
7
Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.皮下给药后用于肝细胞基因沉默的 siRNA 的脂质纳米粒制剂的开发。
J Control Release. 2014 Dec 28;196:106-12. doi: 10.1016/j.jconrel.2014.09.025. Epub 2014 Oct 5.
8
Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.了解 pH 敏感阳离子脂质的构效关系有助于合理鉴定有前途的用于体内递送 siRNA 的脂质纳米粒。
J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2.
9
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.脂质纳米颗粒 siRNA 系统在体内沉默人前列腺癌细胞中的雄激素受体。
Int J Cancer. 2012 Sep 1;131(5):E781-90. doi: 10.1002/ijc.27361. Epub 2012 Jan 3.
10
Rational design of cationic lipids for siRNA delivery.阳离子脂质体的 siRNA 递呈的合理设计。
Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17.

引用本文的文献

1
RNA Therapeutics: Bridging Discovery and Clinical Implementation.RNA疗法:连接发现与临床应用
Methods Mol Biol. 2025;2965:1-37. doi: 10.1007/978-1-0716-4742-4_1.
2
Mechanism of pH-sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery.用于胞质核酸递送的可电离脂质纳米颗粒的pH敏感两亲性内体逃逸机制
Pharm Res. 2025 Jul 8. doi: 10.1007/s11095-025-03890-8.
3
Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment.功能化壳聚糖作为CRISPR-Cas9在癌症治疗中的纳米递送平台。
Asian J Pharm Sci. 2025 Jun;20(3):101041. doi: 10.1016/j.ajps.2025.101041. Epub 2025 Feb 26.
4
Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.肽修饰的脂质纳米颗粒增强RNA疗法的抗肿瘤疗效。
ACS Nano. 2025 Apr 15;19(14):13685-13704. doi: 10.1021/acsnano.4c14625. Epub 2025 Apr 2.
5
Formulation and Characterization of Novel Ionizable and Cationic Lipid Nanoparticles for the Delivery of Splice-Switching Oligonucleotides.用于递送剪接转换寡核苷酸的新型可电离阳离子脂质纳米颗粒的制备与表征
Adv Mater. 2025 Apr;37(17):e2419538. doi: 10.1002/adma.202419538. Epub 2025 Mar 16.
6
Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models - a comprehensive review.脂质纳米颗粒递送的抗病毒小干扰RNA疗法在动物模型中的临床前测试——综述
Drug Deliv Transl Res. 2025 Feb 25. doi: 10.1007/s13346-025-01815-x.
7
A Spike-Based mRNA Vaccine Encapsulated in Phospholipid 1,2-Dioleoyl-sn-Glycero-3-PhosphoEthanolamine Containing Lipid Nanoparticles Induced Potent B- and T-Cell Responses Associated with Protection Against SARS-CoV-2 Infection and COVID-19-like Symptoms in Hamsters.一种包裹在含有1,2-二油酰-sn-甘油-3-磷酸乙醇胺的磷脂脂质纳米颗粒中的基于刺突蛋白的mRNA疫苗,在仓鼠中诱导了强效的B细胞和T细胞反应,并与预防SARS-CoV-2感染及类似COVID-19症状相关。
Vaccines (Basel). 2025 Jan 8;13(1):47. doi: 10.3390/vaccines13010047.
8
Ionizable Cationic Lipids and Helper Lipids Synergistically Contribute to RNA Packing and Protection in Lipid-Based Nanomaterials.可离子化阳离子脂质体和辅助脂质体协同作用,有助于脂质纳米材料中 RNA 的包装和保护。
J Phys Chem B. 2024 Oct 17;128(41):10165-10177. doi: 10.1021/acs.jpcb.4c05057. Epub 2024 Oct 4.
9
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery.用于RNA递送的脂质纳米颗粒制剂与制备的综合分析。
Int J Pharm X. 2024 Sep 10;8:100283. doi: 10.1016/j.ijpx.2024.100283. eCollection 2024 Dec.
10
Advances in the study of LNPs for mRNA delivery and clinical applications.mRNA 递送用 LNPs 的研究进展及临床应用。
Virus Genes. 2024 Dec;60(6):577-591. doi: 10.1007/s11262-024-02102-6. Epub 2024 Aug 22.